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Introduction
Integrins are a large family of transmembrane heterodimeric
receptors that, once bound to extracellular matrix proteins,
regulate a variety of cellular processes.[1] As a consequence
of their role in important physiological phenomena, integrin
defects have been implicated in many common diseases.
Hence, it is not surprising that some integrins have become
attractive targets for pharmacological intervention in
a number of pathological conditions.[2] The observation that
aVb3, aVb5 and a5b1 integrin subtypes are essential for tumor
angiogenesis and can be successfully inhibited by small-mol-
ecule ligands has turned them into the focus of cancer re-
search.[3]
Across their extracellular a/b subunit interface containing
the metal ion-dependent adhesion site (MIDAS), integrins
recognize and bind protein ligands through contiguous tri-
peptide sequences, the majority of which are present within
flexible loop regions and contain an acidic residue.[4] Several
integrins, including a5b1 and aV integrins, recognize Arg-
Gly-Asp (RGD) sequences in endogenous ligands. The con-
text of the ligand RGD sequence (flanking residues, three
dimensional presentation) and individual features of the in-
tegrin binding pockets determine the recognition specificity
and efficacy. A major breakthrough for understanding this
interaction at a molecular level came in 2002 when the X-
ray structure of the complex of integrin aVb3 with cyclo-
[Arg-Gly-Asp-d-Phe-N(Me)-Val] (Cilengitide) was re-
vealed.[5] This potent aVb3 ligand was developed by Kessler
and co-workers (Figure 1),[6,7] and is currently in phase III
clinical trials as an angiogenesis inhibitor for patients with
glioblastoma multiforme.[8] The high activity and selectivity
of this derivative has been attributed to an extended confor-
Abstract: The synthesis of eight bifunc-
tional diketopiperazine (DKP) scaf-
folds is described; these were formally
derived from 2,3-diaminopropionic
acid and aspartic acid (DKP-1–DKP-7)
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azinic nitrogen atoms. The bifunctional
diketopiperazines were introduced into
eight cyclic peptidomimetics containing
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it biotinylated vitronectin binding to
the purified integrins avb3 and avb5,
which are involved in tumor angiogen-
esis. Nanomolar IC50 values were ob-
tained for the RGD peptidomimetics
derived from trans DKP scaffolds
(DKP-2–DKP-8). Conformational
studies of the cyclic RGD peptidomi-
metics by 1H NMR spectroscopy ex-
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Monte Carlo/Stochastic Dynamics
(MC/SD) simulations revealed that the
highest affinity ligands display well-de-
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ing intramolecular hydrogen-bonded
turn motifs and an extended arrange-
ment of the RGD sequence [Cb ACHTUNGTRENNUNG(Arg)
CbACHTUNGTRENNUNG(Asp) average distance 8.8 ].
Docking studies were performed, start-
ing from the representative conforma-
tions obtained from the MC/SD simu-
lations and taking as a reference model
the crystal structure of the extracellular
segment of integrin avb3 complexed
with the cyclic pentapeptide, Cilengi-
tide. The highest affinity ligands pro-
duced top-ranked poses conserving all
the important interactions of the X-ray
complex.
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mation of the RGD motif displaying a distance of about 9 
between the Cb atoms of Asp and Arg.
[5]
These observations prompted many other research groups
to investigate the use of conformationally constrained cyclic
RGD peptides and peptidomimetics as active and selective
integrin ligands, encompassing a wide variety of rigid scaf-
folds and featuring 13-, 14-, 15- and 16-membered rings
(Figure 1).[9] Among the successful approaches, we would
like to mention the g-amino acid RGD peptidomimetics
containing a g-aminocyclopentane carboxylic acid or a 4-
aminoproline residue (14-membered ring),[10] the azabicyclic
lactam RGD peptidomimetics (15-membered ring, with the
scaffold mimicking a constrained dipeptide, e.g., ST1646),[11]
and the b-amino acid RGD peptidomimetics, embodying b3-
homoamino acids[12] (13-membered ring) or a cis-b-aminocy-
clopropane carboxylic acid (16-membered ring).[13] Up to
now, a large number of linear or cyclic peptidic and peptido-
mimetic ligands have been developed, which are all related
to the common recognition motif RGD[14] and a few potent
ligands are presently in different stages of clinical trials for
cancer therapy. Notwithstanding these recent achievements,
the discovery of new ligands displaying high activity and se-
lectivity together with an optimal pharmacological profile
still remains a challenge. Moreover, a clear-cut explanation
of the geometrical requirements of the RGD peptidomimet-
ics in their interaction with the different integrins is still
lacking (the above-mentioned X-ray structural information
suffers from a rather coarse resolution).[5]
New bifunctional diketopiperazine (DKP) scaffolds
[DKP-1 (cis) and DKP-2 (trans); Figure 2] were recently de-
veloped, which are formally derived from aspartic acid and
2,3-diaminopropionic acid and bear a carboxylic acid and an
amino functionality.[15] These bifunctional diketopiperazines
were introduced into the 17-membered cyclic RGD peptido-
mimetics cyclo-[DKP-1-RGD] (9) and cyclo-[DKP-2-RGD]
(10 ; Figure 3), and their conformations and biological activi-
ties were investigated.[16] Cyclo-[DKP-2-RGD] (10) effec-
tively inhibited biotinylated vitronectin binding to the puri-
fied avb3 receptor at low nanomolar concentration, whereas
cyclo-[DKP-1-RGD] (9) required a micromolar concentra-
tion.[16] These results were interpreted in terms of a more ex-
tended RGD sequence imparted by the trans geometry of
the diketopiperazine scaffold (DKP-2) to give rise to
a better pre-organization of peptidomimetic 10 for binding
to the integrin receptors. These observations prompted us to
investigate the structural elements of the bifunctional dike-
topiperazine scaffold that are able to influence and possibly
improve the binding of the cyclo-[DKP-RGD] peptidomi-
metics.
Herein we present a full account of our investigations and
report: 1) the synthesis of a number of cyclic RGD peptido-
mimetics containing various diketopiperazine scaffolds with
different stereochemistry and substitution at the piperazinic
nitrogen atoms; 2) the ability of the cyclic RGD peptidomi-
metics to compete with biotinylated vitronectin for binding
to the purified avb3 and avb5 receptors; 3) conformational
studies of the cyclic RGD peptidomimetics in aqueous solu-
tion by 1H NMR spectroscopy experiments; 4) conforma-
tional studies of the cyclic RGD peptidomimetics by Monte
Carlo/Stochastic Dynamics (MC/SD) simulations; 5) docking
studies of the cyclic RGD peptidomimetics in the crystal
structure of the avb3 binding site.
Results and Discussion
Synthesis of the diketopiperazine scaffolds and cyclic RGD
peptidomimetics : A collection of eight diketopiperazines
Figure 1. Potent aVb3 ligands.
Figure 2. Bifunctional DKP scaffolds.
Figure 3. Cyclic RGD peptidomimetics containing bifunctional DKP scaf-
folds.
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(DKP-1–DKP-8) was synthesized, and their stereochemistry
and substitution patterns were varied (Figure 2). In particu-
lar the scaffolds differ in: 1) the relative stereochemistry,
namely cis (DKP-1) or trans (DKP-2–DKP-8); 2) the abso-
lute stereochemistry of the trans scaffolds [3R,6S (DKP-2,
DKP-4, DKP-5) or 3S,6R (DKP-3, DKP-6, DKP-7, DKP-
8)]; 3) the substitution at the endocyclic nitrogen atoms,
which can be either hydrogen or benzyl (DKP-2, DKP-3,
DKP-4, DKP-6, DKP-8) or dibenzyl (DKP-5, DKP-7);
4) the length of the side-arm bearing the carboxylic group,
which can be either carboxymethyl (DKP-1–DKP-7) or car-
boxyethyl (DKP-8).
Two different strategies were devised for the synthesis of
DKP-1–DKP-8, depending on their nitrogen substitution. In
particular, DKP-1, DKP-2 and DKP-3 (bearing a benzyl
group at nitrogen N-4, Figure 2) were prepared by making
use of the serine ligation strategy exemplified in
Scheme 1,[17] starting from either (R)- or (S)-N-(tert-butoxy-
carbonyl)aspartic acid b-allyl ester 11[18] or (R)- or (S)-N-
benzylserine methyl ester 12.[19] Direct coupling of these
fragments (HATU, iPr2NEt or EDC, DMAP) led to the iso-
peptides 14 in high yield, rather than forming the expected
dipeptides 13. As a matter of fact, selective O-acylation of
the unprotected b-hydroxyl group of N-benzylserine methyl
ester is preferred to the formation of the tertiary amide and
the resulting ester bond is stable in solution to O,N-acyl
transfer.[17] The O,N-acyl migration was then triggered by
cleavage of the Boc protecting group and treatment with
a base, which also promoted the simultaneous cyclization to
the diketopiperazine 15. The introduction of the nitrogen
functionality was then realized through a Mitsunobu-type
reaction by using HN3·Tol in a toluene/dichloromethane so-
lution, to obtain azide 16 in a moderate (51%; cis : S,S) to
good yield (80%; trans : S,R or R,S).[20] Finally, a one-pot
Staudinger reduction/Boc protection[21] yielded the DKP
scaffold allyl ester 17, which was de-allylated[22] to give the
amino acid derivatives DKP-1, DKP-2 and DKP-3 in
a quantitative yield.
Scaffold DKP-8, bearing a carboxyethyl side chain, was
obtained through a similar synthesis strategy starting from
(S)-N-benzylserine methyl ester 12 and (R)-N-(tert-butoxy-
carbonyl)glutamic acid g-methyl ester 18 (Scheme 2).[23]
Also in this case, direct coupling of the fragments afforded
the isopeptide 19, which was deprotected and cyclized to the
diketopiperazine 20. Azidation of the CH2OH group
through a Mitsunobu reaction, reduction by catalytic hydro-
genation, protection with Boc2O and final hydrolysis of the
methylester afforded DKP-8.
For the preparation of diketopiperazines DKP-4 and
DKP-6 (bearing a benzyl group at nitrogen N-1, Figure 2),
the coupling of Boc-serine to N-benzyl-aspartic acid diACHTUNGTRENNUNGmeth-
ACHTUNGTRENNUNGylester 21[24] was envisaged (Scheme 3). The serine hydroxyl
group required protection to avoid self-condensation, and
the commercially available Boc-serine tert-butyl ether was
initially treated with N-Bn-Asp dimethyl ester 21 by using
several coupling agents: with HATU,[25] PyBrOP[26] and
DPPA[27] no product was detected; use of the acyl fluoride,
[obtained by treatment of Boc-Ser ACHTUNGTRENNUNG(OtBu) with cyanuric
Scheme 1. Synthesis of DKP-1, DKP-2 and DKP-3 by the serine ligation
strategy. a) EDC·HCl, DMAP, CH2Cl2, 94%; b) TFA/CH2Cl2 1:2;
c) DIPEA, iPrOH, 90% over two steps; d) HN3, DIAD, PPh3, CH2Cl2/
toluene, 51% S,S ; 80% S,R or R,S ; e) Me3P, BocON, THF, 76%; f) pyr-
rolidine, PPh3, [Pd ACHTUNGTRENNUNG(PPh3)4], CH2Cl2, 99%.
Scheme 2. Synthesis of DKP-8 : a) 12, EDC·HCl, DMAP, CH2Cl2, 59%;
b) TFA/CH2Cl2 1:2; c) DIPEA, iPrOH, 93% over two steps; d) HN3,
DIAD, PPh3, CH2Cl2/toluene/DMF; e) H2, Pd/C, THF; f) Boc2O, THF;
g) LiOH, THF/H2O2 1:1, 43% over four steps.
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fluoride] afforded the coupling product in a modest 15%
yield, whereas use of the mixed anhydride [obtained by
treatment of Boc-Ser ACHTUNGTRENNUNG(OtBu) with iBuOCOCl] gave the cor-
responding iso-butyl carbamate. Finally, preformation of the
symmetric Boc-Ser ACHTUNGTRENNUNG(OtBu) anhydride (DCC)[28] and coupling
to N-Bn-Asp dimethyl ester 21 afforded the corresponding
dipeptide 22 in a satisfactory 80% yield (Scheme 3).
In order to simplify the synthesis sequence and avoid the
use of an additional protecting group (tBu), the hydroxyl
group of Boc-Ser-OMe (either l or d)[20a] was directly trans-
formed into the corresponding azide under Mitsunobu con-
ditions in 78% yield (Scheme 4).
The resulting product was then saponified with LiOH and
the freshly prepared acid 23 was treated with DCC to give
the symmetric anhydride 24 in a quantitative yield, which
was isolated by filtering off DCU and solvent evaporation,
and was immediately used in the next synthesis step without
further purification. Coupling of 3-azido-2-N-tert-butoxycar-
bonylaminopropionic anhydride (24) to N-benzyl-aspartic
acid dimethylester (21) occurred in 80% yield, whereas the
subsequent Boc cleavage and cyclization to diketopiperazine
26 were nearly quantitative (Scheme 5).
At this stage, diketopiperazine 26 was split in two por-
tions. One portion was subjected to catalytic hydrogenation
of the azide, Boc protection and final hydrolysis of the
methyl ester to afford diketopiperazines DKP-4 and DKP-6
in 90% overall yield (Scheme 6).
A second portion of diketopiperazine 26 was alkylated at
nitrogen N-4 (benzyl bromide, KHMDS) to afford the corre-
sponding bis-benzylated derivative. One-pot Staudinger re-
duction/Boc protection[21] followed by saponification of the
methyl ester afforded DKP-5 and DKP-7 in 75% overall
yield (Scheme 7).
Diketopiperazines DKP-1–DKP-8 were then incorporated
into the cyclic RGD derivatives 9, 10 and 27–32 (Figure 4).
A solution phase synthesis strategy was adopted, by using
Boc-Arg ACHTUNGTRENNUNG(Mtr), Gly-OBn and Cbz-AspACHTUNGTRENNUNG(OtBu)-OH. The di-
peptide Boc-Arg ACHTUNGTRENNUNG(Mtr)-Gly-OBn was Boc-deprotected and
coupled to the acid of the appropriate diketopiperazine scaf-
fold. Subsequent Boc deprotection of the DKP amino group
and coupling of the aspartic derivative Cbz-Asp ACHTUNGTRENNUNG(OtBu)-OH
afforded the linear peptidomimetic Cbz-AspACHTUNGTRENNUNG(OtBu)-DKP-
Arg ACHTUNGTRENNUNG(Mtr)-Gly-OBn, which was deprotected by hydrogenoly-
sis (Cbz and Bn) and was subjected to macrolactamization
(for detailed conditions, see the Supporting Information).
Scheme 3. Synthesis of dipeptide 22 : a) CH2Cl2, 80%.
Scheme 4. Synthesis of symmetric anhydride 24 : a) HN3, DIAD, PPh3,
THF, 78%; b) LiOH, THF/H2O 1:1, quantitative; c) DCC, CH2Cl2, quan-
titative.
Scheme 5. Synthesis of diketopiperazine 26 : a) CH2Cl2, 80%; b) TFA/
CH2Cl2 1:2; c) DIPEA, iPrOH, 90% over two steps.
Scheme 6. Synthesis of DKP-4 and DKP-6 : a) H2, Pd/C, THF; b) Boc2O,
THF; c) LiOH, THF/H2O 1:1, 90% over three steps.
Scheme 7. Synthesis of DKP-5 and DKP-7: a) KHMDS, BnBr, THF/
DMF 7:3; b) Me3P, BocON, THF; c) LiOH, THF/H2O 1:1, 75% over
four steps.
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Several methodologies were screened for the ring
closure, and the best yields were obtained for all
the products (except 27) by using HATU/HOAT as
coupling agents in a 1:4:4:6 substrate/HATU/
HOAT/iPr2NEt molar ratio and a substrate concen-
tration of 1.4 mm in DMF.[11b] In the case of cyclo-
[DKP-3-RGD] (27) the highest yield (75%) was
obtained by using a 1:3:6 substrate/DPPA/iPr2NEt
molar ratio with the same substrate concentration
(1.4 mm) in DMF.[29] A final side-chain deprotection
(TFA/thioanisole/ethanedithiol/anisole 90:5:3:2)
and preparative HPLC purification afforded the de-
sired compounds 9, 10 and 27–32 for the biological
screening.
In the case of the N-dibenzyl derivatives 29 and
31, the molecules can exist as two different separa-
ble conformers (diastereomers) due to hindered ro-
tation of one ring around the other, in a way remi-
niscent of the ansa-cyclopeptides[30] (i.e., the DKP N-benzyl
group cannot pass inside the macrolactam ring).
With 29, we were able to isolate only one diastereomer,
either because it was formed exclusively or because it was
formed predominantly and the minor one was not detected/
isolated. With 31, two diastereomers were isolated in
a 2(A):1(B) ratio (Figure 5). The two diastereomers were
formed in the macrolactamization step, as shown by the two
sets of peaks (2:1 ratio) in the 1H NMR spectrum (see the
Supporting Information), but co-eluted in the HPLC. How-
ever, after side-chain deprotection, the two diastereomers
could be separated, analyzed and subjected to the binding
assays (vide infra).
Integrin receptor competitive binding assays : The cyclic
RGD peptidomimetics were examined in vitro for their abil-
ity to inhibit biotinylated vitronectin binding to the purified
avb3 and avb5 receptors (Table 1).
Screening assays were performed by incubating the immo-
bilized integrin receptors with various concentrations (1012–
105m) of the RGD ligands 9, 10, 27–32 in the presence of
biotinylated vitronectin (1 mgmL1), and measuring the con-
centration of bound vitronectin in the presence of the com-
petitive ligands. The ability of the new compounds to inhibit
the binding of vitronectin to the isolated avb3 and avb5 re-
ceptors was compared with that of the reference compounds
c ACHTUNGTRENNUNG(RGDfV)[31] and ST1646[11] (Figure 1). The results are col-
lected in Table 1. Low nanomolar values were obtained with
all the ligands except cyclo-[DKP-1-RGD] (9), which incor-
porates a cis DKP, and ligand 31A. The behavior of this last
ligand is peculiar, considering that the diastereomeric com-
pound 31B (see above for the definition of the two diaste-
reomers) is the most potent ligand of this series, and it effec-
tively inhibits the binding of vitronectin to the isolated avb3
receptor in subnanomolar concentration. Interestingly,
unlike reference compounds c ACHTUNGTRENNUNG(RGDfV) and ST1646, the
Figure 4. Cyclic RGD peptidomimetics containing bifunctional DKP scaf-
folds.
Figure 5. Compounds 31A and 31B, diastereomers of 31 due to hindered
rotation.
Table 1. Inhibition of biotinylated vitronectin binding to avb3 and avb5 receptors.




9 cyclo-[DKP-1-RGD] 3898418 >104
10 cyclo-[DKP-2-RGD] 3.22.7 11499
27 cyclo-[DKP-3-RGD] 4.51.1 14925
28 cyclo-[DKP-4-RGD] 7.64.3 2165
29 cyclo-[DKP-5-RGD] 12.25.0 13129
30 cyclo-[DKP-6-RGD] 2.10.6 793
31A cyclo-[DKP-7-RGD]-A 220.282.3 >104
31B cyclo-[DKP-7-RGD]-B 0.20.09 10915
32 cyclo-[DKP-8-RGD] 17.70.1 42037
cyclo-[RGDfV] cyclo-[RGDfV] 3.21.3 7.54.8
ST1646 see Figure 1 1.00.5 1.40.8
[a] IC50 values were calculated as the concentration of compound required for 50% in-
hibition of biotinylated vitronectin binding as estimated by GraphPad Prism software;
all values are the arithmetic mean SD of triplicate determinations.
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RGD peptidomimetics 10 and 27–32 were about 10–500-fold
more selective for the avb3 integrin with respect to the avb5
in this kind of assay.
NMR spectroscopy characterization and conformational
studies : The structure and connectivity of ligands 9, 10 and
27–32 and of their fully protected precursors were unambig-
uously assigned by means of mono- and bidimensional 1H-
and 13C NMR spectroscopy.
The preferred conformations of the cyclic RGD peptido-
mimetics 9, 10 and 27–32 in aqueous solution were then in-
vestigated, with the aim of rationalizing the affinity of these
compounds for the avb3 receptor at a molecular level.
Mono ACHTUNGTRENNUNGdimensional 1H NMR spectroscopy experiments were
conducted to detect intramolecular hydrogen bonds, by
measuring the chemical shift of the NH protons and their
temperature coefficients (Dd/DT). NOESY spectra were re-
corded to investigate both sequential and long-range NOEs
that provide evidence for preferred conformations. The rele-
vant NMR spectroscopy data are summarized in Table 2.
As already mentioned in our preliminary studies,[16] low
affinity ligand 9 exists as an equilibrium of two different
preferred conformations. The NOESY spectrum shows two
mutually exclusive long-range NOE contacts. The cross-
peak between DKP-NH10 and NHAsp (strong) is indicative of
a b-turn conformation at Gly-Asp stabilized by a hydrogen
bond between DKP-NH10 and Arg-C=O (referred to as
type I H-bonding pattern, Figure 6A). The chemical shift
value (d=7.46 ppm) and the Dd/DT value (2 ppbK1) of
the amide proton DKP-NH10 indicate that this proton is
strongly locked in an intramolecularly H-bonded state. The
cross-peak between NHGly and NHAsp (medium) is indicative
of an alternative b-turn conformation at Arg-Gly, stabilized
by a hydrogen bond between Asp-NH and C(8)=O (referred
to as type II H-bonding pattern, Figure 6B).
High affinity ligands 10 and 27 are apparently character-
ized by conformational mobility, as suggested by the values
of chemical shifts and Dd/DT reported in Table 2. The only
exception is proton NH-Asp of 27 (d=7.85 ppm, Dd/DT=
3.5 ppbK1), which might be involved in a type II H-bond-
ing pattern (for definition of type II H-bonding pattern see
Figure 6B). On the other hand, the presence in both cases
of a NOE contact between NHGly and NHArg suggests the
formation of a b-turn motif at DKP-Arg, stabilized by a hy-
drogen bond between NHGly and C(5)=O (referred to as
type III H-bonding pattern, Figure 7). The presence of this
H bond is also supported by the rather upfield chemical
shift value of NHGly in these two ligands (d=8.18 and
8.00 ppm for 10 and 27, respectively) and the relatively low
temperature dependence (5.7 and 4.5 ppbK1, respec-
tively). The similarity of the NMR spectroscopy data and,
hence, of the conformation of these two ligands is quite sur-
prising, considering the opposite configuration of the diketo-
Table 2. 1H NMR spectroscopy and NOE data of cyclic RGD peptidomimetics in water.
Lig- Structure d [ppm] Dd/DT [ppbK1] Significant
and NH1 NH4 NH10 NHArg NHGly NHAsp NH1 NH4 NH10 NHArg NHGly NHAsp NOE contacts
9 cyclo-[DKP-1-RGD] 8.35 – 7.46 8.40 8.75 8.10 7.3 – 2.0 7.0 8.0 3.7 NHAsp–NH10; NHAsp–NHGly
10 cyclo-[DKP-2-RGD] 8.35 – 8.78 8.57 8.18 8.29 8.7 – 10.7 7.0 5.7 7.7 NHArg–NHGly
27 cyclo-[DKP-3-RGD] 8.10 – 8.28 8.80 8.00 7.85 5.7 – 8.5 6.0 4.5 3.5 NHArg–NHGly
28 cyclo-[DKP-4-RGD] – 8.17 7.59 8.29 8.27 8.88 – 9.1 0.7 9.3 8.2 9.3 –
29 cyclo-[DKP-5-RGD] – – 8.58 8.48 8.23 8.42 – – 11.0 7.5 4.7 8.2 NHArg–NHGly
30 cyclo-[DKP-6-RGD] – 8.07 7.90 8.32 8.35 8.80 – 4.9 5.1 7.6 6.7 8.0 NHAsp–NH10; NH4–NH10
31A cyclo-[DKP-7-RGD]-A – – 8.04 8.66 7.93 7.76 – – 7.5 5.0 3.0 1.0 NHArg–NHGly ; NHAsp–NHGly
31B cyclo-[DKP-7-RGD]-B – – 7.72 8.34 8.45 8.55 – – 4.0 7.0 7.0 5.0 NHAsp–NH10
32 cyclo-[DKP-8-RGD] 7.75 – 8.16 8.42 8.27 8.14 5.3 – 8.5 7.2 6.2 5.0 NH1–NHArg
Figure 6. Preferred intramolecular hydrogen-bonded patterns proposed
for compound 9 on the basis of spectroscopic data. The arrows indicate
significant NOE contacts. A) Type I H-bonding pattern, Gly-Asp b-turn
motif. B) Type II H-bonding pattern, Arg-Gly b-turn motif.
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piperazine scaffold [DKP-2 (3R,6S) in 10 ; DKP-3 (3S,6R) in
27], which should impart a different stereochemical orienta-
tion to the two side arms of the diketopiperazine. This con-
formational similarity can be interpreted in terms of a quasi-
enantiomeric structure of the two ligands (excluding the
configuration of the remote RD amino acid side chains,
Figure 7).
High affinity ligands 28 and 30, featuring the diketopiper-
azine scaffolds DKP-4 (3R,6S) and DKP-6 (3S,6R), respec-
tively (with the benzyl substitution at the endocyclic nitro-
gen N-1, instead of N-4), show a different NMR pattern.
In particular, ligand 30 is characterized by a rather strong
NOE contact between NHAsp and NH10 and a moderate one
involving NH4 and NH10. These two contacts are mutually
exclusive and are hence indicative of an equilibrium be-
tween two different conformations, respectively, type I and
type IV binding modes (Figure 8A and B). The hydrogen
bonded status of the two amide protons NH4 and NH10, as
indicated by their rather low temperature dependence (4.9
and 5.1 ppbK1, respectively) and quite upfield chemical
shift values (d=8.07 and 7.90 ppm, respectively) corroborate
this assumption. The type IV H-bonding pattern could fea-
ture a pseudo-b-turn at Asp-DKP stabilized by a hydrogen
bond between NH4 and Gly-C=O (NOE contact between
NH4 and NH10).
Ligand 28, on the other hand, is characterized by the ab-
sence of relevant NOE contacts, a very low temperature de-
pendence (0.7 ppbK1) and a quite upfield chemical shift
value (d=7.59 ppm) for proton NH10. These two features
suggest a type I H-bonding pattern (for definition of type I
H-bonding pattern, Figure 6A or 8A), notwithstanding the
apparent lack of NOE contact between NHAsp and NH10.
The dibenzylated diketopiperazine containing peptidomi-
metics 29 and 31 were eventually studied. Ligand 29 shows
NMR spectroscopy features similar to ligand 10 (for defini-
tion of type III H-bonding pattern, see Figure 7): a NOE
contact between NHGly and NHArg and a rather shielded
NHGly (d=8.23 ppm) with a relatively low temperature coef-
ficient (4.7 ppbK1). As discussed in the synthesis section,
ligand cyclo-[DKP-7-RGD] was obtained as a mixture of
two diastereomers 31A and 31B, the conformations of
which in solution were studied separately. In particular, the
low affinity ligand 31A displayed two mutually exclusive
NOE contacts between NHArg and NHGly and between
NHAsp and NHGly. These three protons, on the other hand,
show also a rather strong hydrogen bonded status, as indi-
cated by their low temperature dependence and, at least for
NHAsp and NHGly, their upfield chemical shift (Table 2).
These data indicate an equilibrium between two different
conformations: one displaying a type III H-bonding pattern
(b-turn at DKP-Arg, Figure 7) and a second one showing
a type II H-bonding pattern (b-turn at Arg-Gly, Figure 6B),
like the low-affinity ligand 9, that is, cyclo-[DKP-1-RGD].
Finally, high affinity ligand 31B shows a single NOE contact
between NHAsp and NH10 and a hydrogen bonded status for
NH10 (d=7.72 ppm and Dd/DT=4 ppbK1, Table 2).
These values are indicative of a type I H-bonding pattern
(Figure 6A or 8A).
Compound 32, containing the carboxyethyl diketopipera-
zine scaffold DKP-8, is characterized by temperature coeffi-
cients of amide protons (Table 2) greater than 5 ppbK1;
this suggests an equilibrium between different conforma-
tions. The NOESY spectrum of this ligand shows a strong
long-range NOE contact that involves DKP-NH1 and NHArg
(Figure 9). This contact is indicative of a conformation stabi-
lized by a hydrogen bond between NH1 and ArgC=O (re-
ferred to as type V H-bonding pattern). The involvement of
NH1 in a hydrogen bond is also confirmed by its relatively
low chemical shift value (d=7.75 ppm).
Computational studies
Conformational analysis : Conformational studies of the
cyclic RGD peptidomimetics were performed by mixed-
mode Metropolis Monte Carlo/Stochastic Dynamics (MC/
SD) simulations,[32] by using the implicit water GB/SA solva-
tion model[33] and the OPLS_2001 force field.[34,35] As out-
lined in the Introduction, a key parameter for the RGD fit-
Figure 7. Preferred intramolecular hydrogen-bonded pattern proposed
for compound 10 and 27 on the basis of spectroscopic data. The arrows
indicate significant NOE contacts. The DKP-Arg b-turn motif is referred
to as type III H-bonding pattern.
Figure 8. Preferred intramolecular hydrogen-bonded pattern proposed
for compound 30 on the basis of spectroscopic data. A) Type I H-bonding
pattern, Gly-Asp b-turn motif. B) Type IV H-bonding pattern, pseudo-b-
turn at Asp-DKP. The arrows indicate significant NOE contacts.
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ting into the active site of the aVb3 integrin is the distance of
about 9  between the Cb atoms of Asp and Arg, imparted
by an extended conformation of the Arg-Gly-Asp se-
quence.[5] In such an extended conformation, the carboxylate
and guanidinium groups are properly positioned to effec-
tively exert their function of electrostatic clamp (vide infra
for the relevant docking studies).
As mentioned in our preliminary studies,[16] three-dimen-
sional structures satisfying long-range NOE contacts were
generated for low affinity ligand 9 by performing two 10 ns
restrained MC/SD simulations and applying the DKP-NH10/
NHAsp or the NHAsp/NHGly distance restraint derived from
the NOESY spectra described in the relevant section above.
More than 90% of the conformations sampled during the
first simulation adopted a non-extended arrangement of the
RGD sequence characterized by a b-turn at Gly-Asp and
the presence of the corresponding hydrogen bond between
DKP-NH10 and Arg-C=O. In addition, the formation of a g-
turn at Gly stabilized by the hydrogen bond between NHAsp
and Arg-C=O was observed for 40% of the simulation. A
CbACHTUNGTRENNUNG(Arg)CbACHTUNGTRENNUNG(Asp) average distance of 7.4  was obtained
during this MC/SD calculation. A representative energy
minimized conformation selected by cluster analysis and
featuring both H bonds is shown in Figure 10A (type I-cis
H-bonding pattern).
Approximately 60% of the conformations sampled during
the simulation of 9 featuring the NHAsp/NHGly distance re-
straint, adopted a non-extended arrangement of the RGD
sequence characterized by a b-turn at Arg-Gly and the cor-
responding hydrogen bond between NHAsp and C(8)=O. In
addition, the formation of a g-turn at Arg stabilized by the
hydrogen bond between NHGly and C(8)=O was observed
for 40% of the simulation. The Cb ACHTUNGTRENNUNG(Arg)CbACHTUNGTRENNUNG(Asp) average
distance in this MC/SD calculation was 6.8 . A representa-
tive energy minimized conformation selected by cluster
analysis and featuring both H bonds is shown in Figure 10B
(type II H-bonding pattern).
The NOESY spectra of high affinity ligands 10 (contain-
ing N-4-benzylated DKP-2, 3R,6S), 27 (containing N-4-ben-
zylated DKP-3, 3S,6R) and 29 (containing N-dibenzylated
DKP-5 3R,6S) showed only one relevant long-range contact
between NHGly and NHArg: this NOE is indicative of a b-
turn motif at DKP-Arg stabilized by a hydrogen bond be-
tween NHGly and C(5)=O (Figure 7, type III H-bonding pat-
tern). The distance restraint corresponding to the NOE con-
tact between NHGly and NHArg was applied in the 10 ns MC/
SD simulations of compounds 10, 27 and 29. More than
90% of the conformations sampled during each of these
simulations adopted an extended arrangement of the RGD
sequence characterized by a pseudo-b-turn at DKP-Arg and
the formation of the corresponding hydrogen bond between
the NHGly and C(5)=O. Interestingly, only for compound 27,
the additional formation of a b-turn at Arg-Gly stabilized by
the hydrogen bond between NHAsp and C(8)=O was ob-
served for 15% of the simulations. These results and the
NMR spectroscopy data (showing d=7.85 ppm and Dd/
DT=3.5 ppbK1 for NHAsp of 27) suggest the contribution
of a type II/type III H-bonding pattern to the conformation-
al equilibrium of 27 (mainly populated by a type III H-
bonding pattern). CbACHTUNGTRENNUNG(Arg)CbACHTUNGTRENNUNG(Asp) average distances of
9.3, 8.8, and 9.1  were obtained during the MC/SD calcula-
tions of 10, 27 and 29, respectively. A representative energy
minimized conformation selected by cluster analysis and
featuring the H bond between the Gly-NH and C(5)=O
(type III H-bonding pattern) is shown in Figure 11A for
RGD peptidomimetic 10.
Due to the absence of relevant long-range NOE contacts,
several 10 ns runs of unconstrained MC/SD simulations
were performed for high affinity ligand 28 (containing N-1-
benzylated DKP-4, 3R,6S) starting from different 3D struc-
tures. Most of the conformations sampled during these simu-
lations adopted an extended arrangement of the RGD se-
quence [CbACHTUNGTRENNUNG(Arg)CbACHTUNGTRENNUNG(Asp) average distance of 8.8 ] and
approximately 40% of them are characterized by a b-turn at
Gly-Asp and the presence of the corresponding hydrogen
bond between DKP-NH10 and Arg-C=O. These results pro-
vide a structural model in agreement with NMR spectrosco-
py data showing a low temperature dependence
Figure 9. Preferred intramolecular hydrogen-bonded pattern (type V H-
bonding pattern) proposed for compound 32 on the basis of spectroscopic
data. The arrows indicate significant NOE contacts.
Figure 10. Structures of 9 as obtained by restrained MC/SD simulations
based on experimental distance information, after energy minimization.
A) Type I-cis H-bonding pattern, g-turn at Gly and bII’-turn at Gly-Asp
[Cb ACHTUNGTRENNUNG(Arg)CbACHTUNGTRENNUNG(Asp)=7.9 ]. B) Type II H-bonding pattern, g-turn at Arg
and bII’-turn at Arg-Gly [Cb ACHTUNGTRENNUNG(Arg)Cb ACHTUNGTRENNUNG(Asp)=6.6 ]. Tube representa-
tion: O, N in dark gray, C in light gray and NH hydrogen atoms in
white; for the sake of clarity, all H atoms bound to carbon are omitted.
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(0.7 ppbK1) and an upfield chemical shift value (d=
7.59 ppm) for proton NH10.
A representative energy minimized conformation selected
by cluster analysis and featuring the H bond between DKP-
NH10 and Arg-C=O (type I-trans H-bonding pattern) is
shown in Figure 11B for RGD peptidomimetic 28. It is
worth noting how the combination of the trans DKP-4 scaf-
fold with the Gly-Asp b-turn occurs by generating an ex-
tended RGD arrangement, whereas the combination of the
cis DKP-1 scaffold with the same secondary motif resulted
in a non-extended RGD disposition (Figure 10A). Accord-
ingly, two type I H-bonding patterns have been defined
(type I-cis and type I-trans), depending on the cis or trans
relative stereochemistry of the diketopiperazine scaffold.
Three-dimensional structures satisfying long-range NOE
contacts were generated for high affinity ligand 30 (contain-
ing N-1-benzylated DKP-6, 3S,6R) by performing two 10 ns
restrained MC/SD simulations and applying the DKP-NH10/
NHAsp or the NH4/NH10 distance restraint derived from
NOESY spectra (Table 2, Figure 8).
Most of the conformations sampled during the first simu-
lation adopted an extended arrangement of the RGD se-
quence [CbACHTUNGTRENNUNG(Arg)CbACHTUNGTRENNUNG(Asp) average distance of 9.0 ] and
approximately 40% of them are characterized by a b-turn at
Gly-Asp and the corresponding hydrogen bond between
DKP-NH10 and Arg-C=O. A representative energy mini-
mized conformation selected by cluster analysis and featur-
ing this H bond is shown in Figure 12A (type I-trans
H bonding pattern). Approximately 70% of the conforma-
tions sampled during the simulation of 30 featuring the
NH4/NH10 distance restraint adopted an extended arrange-
ment of the RGD sequence [CbACHTUNGTRENNUNG(Arg)CbACHTUNGTRENNUNG(Asp) average dis-
tance of 8.8 ] characterized by a pseudo-b-turn at Asp-
DKP and the corresponding hydrogen bond between NH4
and Gly-C=O. In addition, the formation of a g-turn at Asp
stabilized by the hydrogen bond between NH10 and Gly-
C=O was observed for 50% of the simulation. A representa-
tive energy minimized conformation selected by cluster
analysis and featuring these H bonds is shown in Figure 12B
(type IV H-bonding pattern).
Three-dimensional structures satisfying long-range NOE
contacts were generated for RGD peptidomimetic 31 (con-
taining N-dibenzylated DKP-7, 3S,6R) by performing three
10 ns restrained MC/SD simulations and applying the fol-
lowing distance restraints derived from NOESY spectra of
diastereoisomers 31A and 31B (Table 2): in the first simula-
tion a NHArg/NHGly restraint, relevant in 31A, in the second
simulation a NHAsp/NHGly restraint, also relevant in 31A,
and in the third simulation a DKP-NH10/NHAsp restraint, rel-
evant in 31B.
All the conformations sampled during the first two simu-
lations adopted a non-extended arrangement of the RGD
sequence [CbACHTUNGTRENNUNG(Arg)CbACHTUNGTRENNUNG(Asp) average distance of 6.6 ]
characterized by the simultaneous presence of different turn
motifs (pseudo-b-turn at DKP-Arg, g-turn at Gly and
pseudo-b-turn centered at the DKP unit). The structural
models provided by these restrained MC/SD simulations
differ from the conformations hypothesized on the basis of
NMR spectroscopy data of 31A [equilibrium between type
III (pseudo-b-turn at DKP-Arg) and type II (b-turn at Arg-
Gly) H-bonding patterns, see the NMR spectroscopy sec-
tion]. However, also the calculated structures are able to
provide an explanation for the NOE contacts and the NMR
temperature coefficients observed for low affinity ligand
31A.
The distance restraint corresponding to the NOE contact
between DKP-NH10 and NHAsp (observed in the NOESY
spectrum of high affinity ligand 31B) was applied in the
third 10 ns MC/SD simulation of compound 31. Most of the
conformations sampled during this simulation adopted an
extended arrangement of the RGD sequence [CbACHTUNGTRENNUNG(Arg)Cb-
ACHTUNGTRENNUNG(Asp) average distance of 9.0 ] and approximately 50% of
them are characterized by a b-turn at Gly-Asp and the cor-
responding hydrogen bond between DKP-NH10 and Arg-
C=O (type I-trans H-bonding pattern).
Figure 11. Structures of 10 and 28 as obtained by restrained MC/SD sim-
ulations based on experimental distance information, after energy mini-
mization. A) Compound 10, type III H-bonding pattern, distorted inverse
g-turn at Asp and pseudo-b-turn at DKP-Arg [Cb ACHTUNGTRENNUNG(Arg)CbACHTUNGTRENNUNG(Asp)=
9.4 ]. B) Compound 28, type I-trans H-bonding pattern, inverse g-turn
at Asp and distorted bII’-turn at Gly-Asp [Cb ACHTUNGTRENNUNG(Arg)Cb ACHTUNGTRENNUNG(Asp)=9.0 ].
Tube representation: O, N in dark gray, C in light gray and NH hydro-
gen atoms in white; for the sake of clarity, all H atoms bound to carbon
are omitted.
Figure 12. Structures of 30 as obtained by restrained MC/SD simulations
based on experimental distance information, after energy minimization.
A) Type I-trans H-bonding pattern, inverse g-turn at Asp and distorted
bII’-turn at Gly-Asp [Cb ACHTUNGTRENNUNG(Arg)CbACHTUNGTRENNUNG(Asp)=9.0 ]. B) Type IV H-bonding
pattern, inverse g-turn at Asp and pseudo-b-turn at Asp-DKP [Cb ACHTUNGTRENNUNG(Arg)
Cb ACHTUNGTRENNUNG(Asp)=8.8 ]. Tube representation: O, N in dark gray, C in light gray
and NH hydrogen atoms in white; for the sake of clarity, all H atoms
bound to carbon are omitted.
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Contrary to what was observed for the other cyclic RGD
peptidomimetics containing DKP scaffolds, rotation of the
DKP ring cannot be observed during the simulations per-
formed on compound 31; this confirms 31A and 31B as two
different separable conformers (diastereomers) due to hin-
dered rotation of one ring around the other.
The distance restraint corresponding to the NOE contact
between NH1 and NHArg was applied in the 10 ns MC/SD
simulation of RGD peptidomimetic 32 (containing N-4-ben-
zylated DKP-8, 3S,6R). Approximately 60% of the confor-
mations sampled during this simulation adopted an extend-
ed arrangement of the RGD sequence characterized by the
formation of the hydrogen bond between NH1 and Arg-
C=O (Figure 9, type V H-bonding pattern). In addition, the
formation of the hydrogen bond between NHAsp and
C(2)=O (type Va H-bonding pattern) or the presence of a b-
turn at Gly-Asp stabilized by the hydrogen bond between
DKP-NH10 and Arg-C=O (type Vb H-bonding pattern) were
observed for 35 and 25% of the simulation, respectively.
Representative energy minimized conformations selected
by cluster analysis and featuring the type Va and Vb H-
bonding patterns are shown in Figure 13 for RGD peptido-
mimetic 32.
Molecular docking : In order to rationalize, on a molecular
basis, the affinity of cyclic RGD peptidomimetics for the
avb3 receptor, docking studies were performed by starting
from the representative conformations obtained from the
MC/SD simulations. The crystal structure of the extracellu-
lar segment of integrin avb3 complexed with the cyclic pen-
tapeptide Cilengitide (PDB ID: 1L5G) was taken as a refer-
ence model for the interpretation of the docking results in
terms of ligand–protein interactions.[5] In the X-ray complex,
Cilengitide binds to the interface of the a and b units form-
ing specific electrostatic interactions. The acid and basic
pharmacophoric groups and their orientation are essential
for binding to the avb3 because they act like an electrostatic
clamp, interacting with charged regions of the receptor bind-
ing site.
Docking calculations starting from geometries featuring
the type I-cis and type II H-bonding patterns produced top-
ranked binding modes conserving optimal interactions only
with the a subunit of the avb3 receptor. Probably, the short
CbACHTUNGTRENNUNG(Arg)CbACHTUNGTRENNUNG(Asp) distances (values lower than 8 ) of
these geometries prevent the guanidine and carboxylic
groups from achieving the required separation for binding
to the avb3 integrin. On the other hand, docking calculations
starting from the RGD extended conformations featuring
the type I-trans, type III, type IV and type V H-bonding pat-
terns [Cb ACHTUNGTRENNUNG(Arg)CbACHTUNGTRENNUNG(Asp) distance values 8.8 ] produced
top-ranked binding modes conserving all the important in-
teractions of the X-ray complex. As an example, the best
pose obtained for the highest affinity ligand 31B featuring
the type I-trans H-bonding pattern is shown in Figure 14.
The positively charged Arg guanidinium group of the ligand
interacts with the negatively charged side chains of Asp218
and Asp150 in the a unit, one carboxylate oxygen of the
ligand Asp side chain is coordinated to the metal cation in
the metal-ion-dependent adhesion site (MIDAS) region of
the b unit, whereas the second carboxylate oxygen forms hy-
drogen bonds with the backbone amides of Asn215 and
Tyr122 in the b unit. Further stabilizing interaction involves
the formation of a hydrogen bond between the ligand back-
bone NH of the Asp residue and the backbone carbonyl
group of Arg216 in the b unit. Favorable aromatic ring inter-
actions between the ligand benzylic groups and the b3-
Tyr122 side chain could also be observed (Figure 14).
In light of all these considerations, the micromolar affinity
of RGD peptidomimetics 9 and 31A (3.9 and 0.2 mm, respec-
tively) for avb3 (Table 1) can be explained in terms of their
Figure 13. Structures of 32 as obtained by restrained MC/SD simulation
based on experimental distance information, after energy minimization.
A) Type Va H-bonding pattern [Cb ACHTUNGTRENNUNG(Arg)Cb ACHTUNGTRENNUNG(Asp)=9.9 ]. B) Type Vb
H-bonding pattern [CbACHTUNGTRENNUNG(Arg)Cb ACHTUNGTRENNUNG(Asp)=9.1 ]. Tube representation: O,
N in dark gray, C in light gray and NH hydrogen atoms in white; for
the sake of clarity, all H atoms bound to carbon are omitted.
Figure 14. Docking best pose of compound 31B (type I-trans H-bonding
pattern, atom color tube representation) into the crystal structure of the
extracellular domain of avb3 integrin (a unit red and b unit blue wire rep-
resentation) overlaid on the bound conformation of Cilengitide (green
tube representation). Only selected integrin residues involved in the in-
teractions with the ligand are shown. The Mn2+ ion at MIDAS is shown
as a magenta CPK sphere. For the sake of clarity, all H atoms bound to
carbon are omitted.
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low pre-organization for binding. In fact, as determined by
the computational and NMR spectroscopy studies, in solu-
tion these compounds mainly feature non-extended RGD
conformations, which according to the docking results, are
not able to properly fit into the avb3 receptor. On the con-
trary, the nanomolar affinity of RGD peptidomimetics 10,
27–30, 31B and 32 for avb3 can be attributed to their high
structural pre-organization. In fact, as determined by the
computational and NMR spectroscopy studies, these com-
pounds in solution mainly feature extended RGD conforma-
tions (principally determined by type I-trans, type III,
type IV and type V H-bonding patterns) similar to the RGD
bound conformation of Cilengitide.
Conclusion
In summary, we have synthesized a small library of bifunc-
tional diketopiperazine (DKP) scaffolds, which were formal-
ly derived from 2,3-diaminopropionic acid and aspartic acid
(DKP-1–DKP-7) or glutamic acid (DKP-8) and feature an
amine and a carboxylic acid functional group. The scaffolds
differ for the configuration at the two stereocenters and the
substitution at the diketopiperazinic nitrogen atoms. The bi-
functional diketopiperazines were introduced into eight
cyclic peptidomimetics containing the Arg-Gly-Asp (RGD)
sequence. The resulting RGD peptidomimetics were
screened for their ability to inhibit biotinylated vitronectin
binding to the purified integrins avb3 and avb5, which are in-
volved in tumor angiogenesis. Nanomolar values were ob-
tained for the RGD peptidomimetics derived from trans
DKP scaffolds (DKP-2–DKP-8). Conformational studies of
the cyclic RGD peptidomimetics by 1H NMR spectroscopy
experiments (VT-NMR and NOESY) in aqueous solution
and Monte Carlo/Stochastic Dynamics (MC/SD) simulations
revealed that the highest affinity ligands display well-de-
fined preferred conformations featuring intramolecular hy-
drogen-bonded turn motifs and an extended arrangement of
the RGD sequence [CbACHTUNGTRENNUNG(Arg)Cb ACHTUNGTRENNUNG(Asp) average distance
8.8 ]. Docking studies were performed, starting from the
representative conformations obtained from the MC/SD
simulations and taking as a reference model the crystal
structure of the extracellular segment of integrin avb3 com-
plexed with the cyclic pentapeptide, Cilengitide. The highest
affinity ligands produced top-ranked poses conserving all
the important interactions of the X-ray complex.
Experimental Section
A detailed procedure for the synthesis of intermediate 15 starting from
protected amino acid derivatives 11 and 12 was already reported.[16] The
same procedure was used for the synthesis of intermediate 20, starting
from protected amino acid derivatives 18 and 12. Diketopiperazine 26
ring closure was achieved under similar conditions by using Et3SiH
(2.5 equiv) as a scavenger during Boc cleavage.
General procedure for the synthesis of diketopiperazine azides : PPh3
(1.5 equiv) was added to a solution of diketopiperazines 15 or 20
(1 equiv) in CH2Cl2/toluene (2:1) under a nitrogen atmosphere and at
20 8C, and the mixture was stirred until a solution was obtained. Hydra-
zoic acid (1.5m in toluene, 3 equiv) was added followed by dropwise addi-
tion of DIAD (1.5 equiv) and the reaction was stirred at 20 8C for 3–
16 h. The reaction mixture was loaded onto a silica gel column and puri-
fied by flash chromatography (for solvents and ratios used, see the Sup-
porting Information) to afford the desired product as a white foam (69–
86%).
General procedure for the synthesis of dipeptide 25 : DCC (1 equiv) was
added to a solution of either (R)- or (S)-N-Boc-Ser(N3)-OH (23 ; 2 equiv)
in CH2Cl2, in one portion. A white precipitate (DCU) formed and stirring
was continued for 1 h at room temperature. The mixture was then filtered
on cotton wool to remove DCU. The white DCU residue was washed
twice with cold CH2Cl2. The filtrate was concentrated under reduced
pressure at room temperature, and dried under high vacuum to afford
symmetric anhydride 24 as a pale yellow foam, which was used without
further purification. Either (R)- or (S)-N-benzyl-aspartic acid dimethyl-
ACHTUNGTRENNUNGester (0.7 equiv) was dissolved in CH2Cl2 and the mixture was cooled to
0 8C. A solution of symmetric anhydride in CH2Cl2 was then added drop-
wise (very slowly). The reaction mixture was allowed to reach room tem-
perature and was stirred at room temperature, overnight. The solvent
was then removed under reduced pressure and the residue was purified
by flash chromatography (hexane/EtOAc 8:2) on silica gel to afford the
desired product as a viscous transparent oil (80%).
General diketopiperazine N-benzylation procedure : A flame-dried flask
under N2 was charged with a solution of 26 (1 equiv) in dry THF. The
temperature was lowered to 78 8C and KHMDS (0.5m solution in tolu-
ene, 1.1 equiv) was added dropwise. After 30 min benzyl bromide
(5 equiv) was added, and a final solvent ratio THF/DMF 7:3 was reached
by adding DMF. The mixture was allowed to reach 40 8C and stirred for
3 h. Then aqueous NH4Cl was slowly added and the mixture was extract-
ed with EtOAc (3). The organic phases were then washed with brine
and dried over Na2SO4. Volatiles were removed under reduced pressure
and the residue was purified by flash chromatography on silica gel to
afford the desired product as a viscous transparent oil (86%).
General procedure for diketopiperazine azide reduction and Boc protec-
tion : A) 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON,
2.2 equiv) and Me3P (1m solution in toluene, 2 equiv) were added succes-
sively to a solution of diketopiperazine azide (1 equiv) in THF, under a ni-
trogen atmosphere and at 20 8C. After being stirred for 6 h at room
temperature, the solution was diluted with CH2Cl2 and washed with H2O
(3) and brine. The organic phase was dried over Na2SO4 and volatiles
were removed under reduced pressure. The residue was purified by flash
chromatography (for solvents and ratios used, see the Supporting Infor-
mation) on silica gel to afford the desired product as a white foam (76–
87%).
B) Diketopiperazine azide (1 equiv) was dissolved in THF and Pd/C
(0.1 equiv) was added. The flask was thoroughly purged with H2, and the
system was closed. The reaction mixture was stirred at room temperature
for 4 h, and then filtered through a Celite pad. The cake thus obtained
was thoroughly washed with THF. The filtrate was concentrated and
dried to give the crude product as a transparent paste (95%), which was
dissolved in THF (35 mL). Boc2O (1.1 equiv) was then added in one por-
tion. After stirring the mixture at room temperature, overnight, EtOAc
was added. The solution was washed with KHSO4 (1m ; 4) and brine
(1). The organic phase was dried over Na2SO4 and volatiles were re-
moved under reduced pressure, to afford the desired product as a white
foam (95%), which was used without further purification.
General procedure for diketopiperazine allyl ester deprotection : Diketo-
piperazine allyl ester (1 equiv) was dissolved in CH2Cl2 under a nitrogen
atmosphere. After cooling the solution at 0 8C, pyrrolidine (1.2 equiv),
PPh3 (0.18 equiv) and [PdACHTUNGTRENNUNG(PPh3)4] (0.04 equiv) were added successively.
After being stirred for 1 h at 0 8C, the mixture was diluted with EtOAc
and extracted with aqueous NaHCO3 (4). The combined aqueous
phases were acidified to pH 2 with a KHSO4 (1m) solution and then ex-
tracted with CH2Cl2. The resulting organic phase was dried over Na2SO4
and the solvent was evaporated to afford the desired product as a fluffy
white solid (99%).
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Procedure for diketopiperazine methyl ester hydrolysis : A) Diketopiper-
azine methyl ester (1 equiv) was dissolved in THF and the mixture was
cooled to 0 8C. A solution of LiOH·H2O (2.5 equiv) in H2O was added
dropwise. The resulting solution was stirred for 1 h at 0 8C. Then, main-
taining the temperature at 0 8C, the mixture was acidified with HCl (1m)
to pH 1–2, and extracted with CH2Cl2 (4). The collected organic phases
were dried over Na2SO4 and volatiles were removed under reduced pres-
sure. Either DKP-4 or DKP-6 were afforded as a white foam (100%).
B) Diketopiperazine methyl ester (1 equiv) was dissolved in THF. The
mixture was cooled to 0 8C and a solution of LiOH (2.7m) in H2O2 (35%
v/v) was added dropwise. The mixture was stirred for an additional
30 min at 0 8C, then warmed to room temperature and stirred for 7 h.
After addition of Na2SO3 (6 equiv) the reaction mixture was diluted with
THF/H2O (1:1). KHSO4 (1m) was then added until pH 1–2 was reached,
and the mixture was extracted with DCM (4). The collected organic
phases were dried over Na2SO4 and volatiles removed under reduced
pressure, to afford crude DKP-8 as a yellowish solid. The crude product
was dissolved in EtOAc and extracted with a saturated NaHCO3 aqueous
solution; collected aqueous layers were acidified with KHSO4 (1m) to
reach pH 1–2, and extracted with DCM (4). Collected organic phases
were dried over Na2SO4 and volatiles were removed under reduced pres-
sure, to afford DKP-8 as a white foam (90%).
General procedure for Boc deprotection reactions : A half volume of
TFA was added to a solution of the N-Boc-protected amino acid or pep-
tide in CH2Cl2 (0.13m). The reaction mixture was stirred for 2 h at room
temperature and then concentrated at reduced pressure. Excess TFA was
azeotropically removed from the residue with toluene. Diethyl ether was
added to the residue and the resulting suspension was evaporated under
reduced pressure to afford the corresponding TFA salt.
General procedure for coupling reactions : HATU (1.2 equiv), HOAt
(1.2 equiv) and DIPEA (4 equiv) were added successively to a solution
of the N-protected amino acid in DMF, under a nitrogen atmosphere and
at 0 8C. After 30 min, a solution of the N-deprotected TFA salt of the
peptide in DMF was added and the reaction mixture was stirred at 0 8C
for 1 h and at room temperature, overnight. The mixture was then diluted
with EtOAc and consecutively washed with KHSO4 (1m ; 2), a saturated
NaHCO3 aqueous solution (2), brine (2), and dried over Na2SO4. Vol-
atiles were evaporated under reduced pressure to afford the crude prod-
uct.
General procedure for Cbz and OBn hydrogenolytic cleavage : Protected
compound (1 equiv) was dissolved in a mixture of THF/H2O (1:1) and
Pd/C 10% (0.1 equiv) was added. The reaction mixtures were subjected
to three vacuum/hydrogen cycles and then stirred, overnight, at room
temperature under 1 bar of hydrogen. The mixture was filtered through
Celite, and the cake thus obtained was washed thoroughly with THF/
H2O (1:1). The filtrate was concentrated and dried to give the crude
product as white solid (100%).
General procedure for macrolactamization : HATU (4 equiv), HOAt
(4 equiv) and DIPEA (6 equiv) were added successively to a solution of
deprotected linear compound (1.4 mm ; 1 equiv) in DMF, under a nitrogen
atmosphere at 0 8C. After stirring the reaction mixture at 0 8C for 1 h, it
was allowed to reach room temperature and stirred, overnight. DMF was
then removed under reduced pressure and the residue was purified by
flash chromatography (CH2Cl2/MeOH; for ratios used, see the Support-
ing Information) on silica gel to afford the product as white foam (31–
74%).
Solid-phase receptor-binding assay : Purified avb3 and avb5 receptors
(Chemicon International, Inc., Temecula, CA) were diluted to
0.5 mgmL1 in coating buffer containing Tris-HCl (20 mmolL1; pH 7.4),
NaCl (150 mmolL1), MnCl2 (1 mmolL
1), CaCl2 (2 mmolL
1) and
MgCl2 (1 mmolL
1). An aliquot of diluted receptors (100 mL per well)
was added to 96-well microtiter plates (Nunc MW 96F Medisorp
Straight) and incubated, overnight, at 4 8C. The plates were then incubat-
ed with blocking solution (coating buffer plus 1% bovine serum albumin)
for an additional 2 h at room temperature to block nonspecific binding
followed by 3 h incubation at room temperature with various concentra-
tions (1012–105m) of test compounds in the presence of vitronectine
(1 mgmL1) biotinylated by using EZ-Link Sulfo-NHS-Biotinylation kit
(Pierce, Rockford, IL). After washing, the plates were incubated for 1 h
at room temperature with streptavidin–biotinylated peroxidase complex
(Amersham Biosciences, Uppsala, Sweden) followed by 30 min incuba-
tion with substrate reagent solution (100 mL; R&D Systems, Minneapolis,
MN) before stopping the reaction by addition of H2SO4 (2N, 50 mL). Ab-
sorbance at 415 nm was read in a Synergy HT multi-detection micro-
plate reader (BioTek Instruments, Inc.). Each data point is the result of
the average of triplicate wells and was analyzed by nonlinear regression
analysis with Prism GraphPad program. Each experiment was repeated
in triplicate.
General procedure for Mtr and OtBu ester removal: Protected macrolac-
tams were treated with TFA (0.01m) in the presence of ion scavengers:
thioanisole (5%), ethanedithiol (3%), anisole (2%). After TFA removal,
under reduced pressure, the residue was dissolved in a 1:1 mixture of di-
ACHTUNGTRENNUNGisopropyl ether/water. Phases were separated and the aqueous layer was
washed several times with diisopropyl ether. The aqueous phase was con-
centrated under reduced pressure to give the crude product, which was
purified by HPLC to give the desired compound as white solid (60–
80%).
NMR spectroscopy studies : NMR spectroscopy experiments were per-
formed at a temperature of 298 K on Bruker Avance 400 and 600 MHz
spectrometers. All proton and carbon chemical shifts were assigned un-
ambiguously. The NMR experiments were carried out in a D2O/H2O 1:9
mixture in order to observe amide protons. Two-dimensional experiments
(TOCSY, NOESY, and HSQC) were carried out on samples of cyclic
RGD peptidomimetics 9, 10, 27–32 at a concentration range of 3–6 mm.
NOESY experiments were performed at 0.7 or 0.8 s. The water resonance
was saturated with the excitation sculpting sequence from the Bruker li-
brary. The conformations of the cyclic pentapeptides were analyzed with
respect to hydrogen bonding of amide protons (VT-NMR spectroscopy)
and NOE contacts.
Computational studies : All calculations were run by using the Schrçding-
er suite of programs (http://www.schrodinger.com) through the Maestro
graphical interface.
Conformational analysis : Conformational preferences of the RGD pepti-
domimetics were investigated by Monte Carlo/Stochastic Dynamics (MC/
SD) hybrid simulations[32] by using the NMR spectroscopy restraints de-
rived from the experimental NOE contacts (for distance restraints used
for each calculation, see the Supporting Information). All the NOE re-
straints were set to a distance value of 2 ACHTUNGTRENNUNG(0.5)  with a force constant of
100 kJmol12. MC/SD simulations were performed at 300 K within the
framework of MacroModel version 9.5[36] by employing the OPLS_2001
force field[34] and the implicit water GB/SA solvation model.[33] RGD
side-chain dihedral angles were defined as internal coordinate degrees of
freedom in the Monte Carlo part of the algorithm. A time step of 1 fs
was used for the stochastic dynamics (SD) part of the algorithm for 10 ns
of simulation time. Samples were taken at 2 ps intervals during each sim-
ulation, yielding 5000 conformations for analysis. The percentages of
H bonds discussed here were calculated as percentages of conformations
sampled during the simulation in which donor H–acceptor O distance
<2.5  (g-turn) or <4  (b-turn).
Molecular docking : The recently solved crystal structure of the extracel-
lular domain of the integrin avb3 receptor in complex with Cilengitide
and in the presence of the proadhesive ion Mn2+ (PDB ID: 1L5G)[5] was
used for docking studies. Docking was performed only on the globular
head of the integrin because the headgroup of integrin has been identi-
fied in the X-ray structure as the ligand-binding region. The protein
structure was setup for docking as follows. The protein was truncated to
residue sequences 41–342 for chain a and 114–347 for chain b. Due to
a lack of parameters, the Mn2+ ions in the experimental protein structure
were modeled by replacing them with Ca2+ ions. The resulting structure
was prepared by using the Protein Preparation Wizard of the graphical
user interface Maestro and the OPLSAA force field. The automated
docking calculations were performed by using Glide[37] (Grid-based
Ligand Docking with Energetics). The grid generation step started from
the extracellular fragment of X-ray structure of avb3 complex with Cilen-
gitide, as described in the protein setup section. The center of the grid
enclosing box was defined by the center of the bound ligand, as described
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in the original PDB entry. The enclosing box dimensions, which are auto-
matically deduced from the ligand size, fit the entire active site. For the
docking step, the size of the bounding box for placing the ligand center
was set to 12 . No further modifications were applied to the default set-
tings. The GlideScore function was used to select 20 poses for each
ligand. The Glide program was initially tested for its ability to reproduce
the crystallized binding geometry of Cilengitide. The program was suc-
cessful in reproducing the experimentally determined binding mode of
this compound, as it corresponds to the best-scored pose.
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